Brooklyn Investment Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Brooklyn Investment Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-181	Closed	-$23.9K	–	3434
2025 Q1	$23.9K	Buy	181 +156	+624%	+$19.4K	0.01%	1074
2024 Q4	$2.09K	Buy	+25	New	+$2.05K	﹤0.01%	1447

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Brooklyn Investment Group's ITCI Position: Q2 2025 in Review

Brooklyn Investment Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 181 shares — an estimated $23.9K sold.

Brooklyn Investment Group first reported a position in ITCI in Q4 2024 and held it in 2 quarters. The position peaked at $23.9K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Brooklyn Investment Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Brooklyn Investment Group sold 181 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $23.9K.
Brooklyn Investment Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2024 and held it in 2 quarters.
Brooklyn Investment Group's Intra-Cellular Therapies Inc. position peaked at $23.9K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Brooklyn Investment Group's 13F filing for Q2 2025, filed 12 Aug 2025.